Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID-19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS-CoV-2 infection status of alopecia areata patients; and the relationships of recurrence to age, gender, treatment duration, and tofacitinib discontinuation. One-hundred and ninety-one (61.4%) patients were off the drug and 120 (38.6%) were on therapy during the pandemic. The relationship between drug discontinuation due to the COVID-19 pandemic and recurrence was statistically significant (P
CITATION STYLE
Aşkın, Ö., Özkoca, D., Uzunçakmak, T. K., & Serdaroğlu, S. (2021). Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatologic Therapy, 34(2). https://doi.org/10.1111/dth.14746
Mendeley helps you to discover research relevant for your work.